30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

ConMed 4Q17 Arthroscopy/Soft Tissue Revenue +8% vs. 4Q16 -

ConMed posted 4Q17 arthroscopy/soft tissue repair revenue of US $121.0MM, +8.4% vs. 4Q16, and 2017 revenue of $428.9MM, +1.6% vs. the prior year. Growth is attributed to new product introductions, updated purchasing contracts and a focus on salesforce development.

  4Q17  4Q16  $ Change  % Change 
 Arthroscopy/Soft Tissue Repair $121.0  $111.6  $9.4  8.4% 


  2017  2016  $ Change  % Change 
 Arthroscopy/Soft Tissue Repair $429.0  $422.2  $6.8  1.6% 


ConMed’s orthopaedic revenue returned to growth for the first time in seven quarters. Both U.S. and international orthopaedic revenue posted growth, at +5.3% and +10.5% for4Q17 vs. 4Q16. Leadership noted that investments in people and products are materializing on a more consistent basis.

The revitalization of CNMD’s “innovation engine” was supported by people and products, beginning with the appointment of Mr. Nathan Folkert as VP and GM of Orthopaedics in 2H15.

Rollouts and some tuck-in M&A along the way have been a part of the growth story, including the 4Q15 acquisition of KFx Medical’s AppianFx soft tissue fixation and an early-3Q17 acquisition of MedShape’s ExoShape Anterior Cruciate Ligament fixation. Launches included the ARC Adjustable Retractor Cannula for the shoulder, the AssistArm limb positioner, the Edge Bi-Polar Arthroscopic RF System and the Tenolok Dual Expanding Tenodesis anchor. Leadership suggested that additional announcements will be made at AAOS 2018 highlighting activity from the ortho R&D pipeline.

Source: ConMed Corporation

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.